- Home
- STRW vs GLSI Comparison
STRW vs GLSI Comparison
Compare STRW & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- GLSI
- Stock Information
- Founded
- STRW 2015
- GLSI 2006
- Country
- STRW United States
- GLSI United States
- Employees
- STRW N/A
- GLSI N/A
- Industry
- STRW Real Estate Investment Trusts
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- GLSI Health Care
- Exchange
- STRW Nasdaq
- GLSI Nasdaq
- Market Cap
- STRW 123.8M
- GLSI 134.6M
- IPO Year
- STRW N/A
- GLSI 2020
- Fundamental
- Price
- STRW $12.13
- GLSI $12.18
- Analyst Decision
- STRW Strong Buy
- GLSI Strong Buy
- Analyst Count
- STRW 4
- GLSI 1
- Target Price
- STRW $12.72
- GLSI $39.00
- AVG Volume (30 Days)
- STRW 29.9K
- GLSI 45.1K
- Earning Date
- STRW 08-08-2025
- GLSI 08-14-2025
- Dividend Yield
- STRW 4.86%
- GLSI N/A
- EPS Growth
- STRW 27.31
- GLSI N/A
- EPS
- STRW 0.59
- GLSI N/A
- Revenue
- STRW $135,145,000.00
- GLSI N/A
- Revenue This Year
- STRW $32.86
- GLSI N/A
- Revenue Next Year
- STRW $3.50
- GLSI N/A
- P/E Ratio
- STRW $20.62
- GLSI N/A
- Revenue Growth
- STRW 24.72
- GLSI N/A
- 52 Week Low
- STRW $8.70
- GLSI $8.06
- 52 Week High
- STRW $12.90
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- STRW 69.75
- GLSI 56.92
- Support Level
- STRW $11.32
- GLSI $11.41
- Resistance Level
- STRW $12.00
- GLSI $12.35
- Average True Range (ATR)
- STRW 0.52
- GLSI 0.67
- MACD
- STRW 0.17
- GLSI -0.06
- Stochastic Oscillator
- STRW 95.09
- GLSI 52.20
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.